特发性血小板减少性紫癜(ITP)是临床最为常见的出血性疾病,约占出血性疾病总数的30%。治疗以糖皮质激素、脾切除、免疫抑制剂等非特异性手段为主,但副反应明显,约1/3的患者治疗无效,成为难治性ITP。近年对ITP自身免疫发病机制的深入研究令许多新的定向免疫干预措施开始进入临床 Idiopathic thrombocytopenic purpura (ITP) is the most common clinical bleeding disorders, accounting for about 30% of the total number of bleeding disorders. Treatment with glucocorticoid, splenectomy, immunosuppressive agents and other non-specific means of the main, but significant side effects, about 1/3 of patients treated ineffective, a refractory ITP. In recent years, the in-depth study of the pathogenesis of ITP autoimmune has led to many new targeted immunological interventions into clinical practice